AIM: To examine whether the fasting levels of serum gastrin-17 (G-17) are lower in Barrett's esophagus (BE) patients than in non-Barrett controls. METHODS: Nineteen patients with BE (presenting with a tubular segment > or =2 cm long in lower esophagus and intestinal metaplasia of incomplete type ("pecialized columnar epithelium") in endoscopic biopsies from the tubular segment below the squamocolumnar junction were collected prospectively from outpatients referred to diagnostic gastroscopy. The controls comprised 199 prospectively collected dyspeptic outpatients without BE or any endoscopically visible lesions in the upper GI tract. Fasting levels of serum G-17 (G-17fast) were assayed with an EIA test using a mAb highly specific to amidated G-17. None of the patients and controls received therapy with PPIs or other antisecretory agents. RESULTS: The mean and median levels of G-17fast in serum were significantly lower (P = 0.001) in BE patients than in controls. The positive likelihood ratios (LR+) of low G-17fast to predict BE in the whole study population at G-17fast levels <0.5, <1, or <1.5 pmol/L were 3.5, 3.0, and 2.8, respectively. Among patients and controls with healthy stomach mucosa, the LR+ were 5.6, 3.8, and 2.6, respectively. In the whole study population, serum G-17 was below 2 pmol/L in 15 of 19 BE patients (79%). The corresponding prevalence was 66 of 199 (33%) in controls (P<0.001). The G-17fast was 5 pmol/L or more in only one of the 19 BE patients (5%). In controls, 76 of the 199 patients (38%) had such high serum G-17fast levels (P<0.01). CONCLUSION: Serum levels of G-17fast tend to be lower in native patients with BE than in healthy controls.
AIM: To examine whether the fasting levels of serum gastrin-17 (G-17) are lower in Barrett's esophagus (BE) patients than in non-Barrett controls. METHODS: Nineteen patients with BE (presenting with a tubular segment > or =2 cm long in lower esophagus and intestinal metaplasia of incomplete type ("pecialized columnar epithelium") in endoscopic biopsies from the tubular segment below the squamocolumnar junction were collected prospectively from outpatients referred to diagnostic gastroscopy. The controls comprised 199 prospectively collected dyspeptic outpatients without BE or any endoscopically visible lesions in the upper GI tract. Fasting levels of serum G-17 (G-17fast) were assayed with an EIA test using a mAb highly specific to amidated G-17. None of the patients and controls received therapy with PPIs or other antisecretory agents. RESULTS: The mean and median levels of G-17fast in serum were significantly lower (P = 0.001) in BE patients than in controls. The positive likelihood ratios (LR+) of low G-17fast to predict BE in the whole study population at G-17fast levels <0.5, <1, or <1.5 pmol/L were 3.5, 3.0, and 2.8, respectively. Among patients and controls with healthy stomach mucosa, the LR+ were 5.6, 3.8, and 2.6, respectively. In the whole study population, serum G-17 was below 2 pmol/L in 15 of 19 BE patients (79%). The corresponding prevalence was 66 of 199 (33%) in controls (P<0.001). The G-17fast was 5 pmol/L or more in only one of the 19 BE patients (5%). In controls, 76 of the 199 patients (38%) had such high serum G-17fast levels (P<0.01). CONCLUSION: Serum levels of G-17fast tend to be lower in native patients with BE than in healthy controls.
Authors: Yvonne Romero; Alan J Cameron; Daniel J Schaid; Shannon K McDonnell; Lawrence J Burgart; Cyndy L Hardtke; Joseph A Murray; G Richard Locke Journal: Am J Gastroenterol Date: 2002-05 Impact factor: 10.864
Authors: H Väänänen; M Vauhkonen; T Helske; I Kääriäinen; M Rasmussen; H Tunturi-Hihnala; J Koskenpato; M Sotka; M Turunen; R Sandström; M Ristikankare; A Jussila; P Sipponen Journal: Eur J Gastroenterol Hepatol Date: 2003-08 Impact factor: 2.566
Authors: Tan Han Loong; Ngiu Chai Soon; Nik Ritza Kosai Nik Mahmud; Jeevinesh Naidu; Rafiz Abdul Rani; Nazefah Abdul Hamid; Marjanu Hikmah Elias; Isa Mohamed Rose; Azmi Tamil; Norfilza M Mokhtar; Raja Affendi Raja Ali Journal: Biomed Rep Date: 2017-09-20
Authors: Lars Agréus; Ernst J Kuipers; Limas Kupcinskas; Peter Malfertheiner; Francesco Di Mario; Marcis Leja; Varocha Mahachai; Niv Yaron; Martijn van Oijen; Guillermo Perez Perez; Massimo Rugge; Jukka Ronkainen; Mikko Salaspuro; Pentti Sipponen; Kentaro Sugano; Joseph Sung Journal: Scand J Gastroenterol Date: 2012-02 Impact factor: 2.423
Authors: Alberto Barchi; Chiara Miraglia; Alessandra Violi; Ginevra Cambiè; Antonio Nouvenne; Mario Capasso; Gioacchino Leandro; Tiziana Meschi; Gian Luigi De' Angelis; Francesco Di Mario Journal: Acta Biomed Date: 2018-12-17
Authors: Silvia Cesario; Serena Scida; Chiara Miraglia; Alberto Barchi; Antonio Nouvenne; Gioacchino Leandro; Tiziana Meschi; Gian Luigi De' Angelis; Francesco Di Mario Journal: Acta Biomed Date: 2018-12-17
Authors: Jaanus Suumann; Toomas Sillakivi; Živile Riispere; Kari Syrjänen; Pentti Sipponen; Ülle Kirsimägi; Ants Peetsalu Journal: BMC Obes Date: 2018-02-20